Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 8/20 | 0.68 |
| ▸ | DPP4 | P27487 | 8/20 | 0.64 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.52 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936544 | 0.86 | ANPEP (0.68) | ANPEPDPP4NR1H2NR1H3PDCD1 | |
| SCHEMBL2818285 | 0.81 | ANPEP (1.00) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL13171786 | 0.80 | ANPEP (0.71) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL2820118 | 0.78 | DPP4 (0.78) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL29366407 | 0.78 | DPP4 (0.78) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL9812636 | 0.78 | ANPEP (0.69) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL173289 | 0.78 | ANPEP (1.00) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL17531021 | 0.77 | ANPEP (0.67) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL30954668 | 0.77 | ANPEP (0.67) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL6925321 | 0.76 | ANPEP (0.66) | ANPEPDPP4NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260143582-A1 | MULTILAYER BODY AND METHOD FOR PRODUCING SAME | TEIJIN LIMITED (JP) | 2026-05-21 | — | — | US | disclosed |
| US-20260078114-A1 | COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF | TYK MEDICINES INC (CN) | 2026-03-19 | — | — | US | disclosed |
| EP-4610045-A1 | MULTILAYER BODY AND METHOD FOR PRODUCING SAME | Teijin Limited (JP) | 2025-09-03 | — | — | EP | disclosed |
| EP-4585595-A1 | COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF | TYK Medicines, Inc. (CN) | 2025-07-16 | — | — | EP | disclosed |
| EP-4109869-B1 | DOCUMENT DETERMINATION SYSTEM, DOCUMENT DETERMINATION METHOD, AND INFORMATION PROCESSING APPARATUS | SEIKO EPSON CORP (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024090364-A1 | MULTILAYER BODY AND METHOD FOR PRODUCING SAME | 帝人株式会社 | 2024-05-02 | — | — | WO | disclosed |
| CN-117645604-A | Compounds useful as CDK4 kinase inhibitors and uses thereof | 浙江同源康医药股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11831827-B2 | Document determination system, document determination method, and information processing apparatus | SEIKO EPSON CORPORATION (JP) | 2023-11-28 | — | — | US | disclosed |
| CN-116288205-A | Tantalum-titanium-zirconium-chromium high-entropy alloy and preparation method thereof | 西安交通大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20220417379-A1 | DOCUMENT DETERMINATION SYSTEM, DOCUMENT DETERMINATION METHOD, AND INFORMATION PROCESSING APPARATUS | SEIKO EPSON CORPORATION (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-4109869-A1 | DOCUMENT DETERMINATION SYSTEM, DOCUMENT DETERMINATION METHOD, AND INFORMATION PROCESSING APPARATUS | Seiko Epson Corporation (JP) | 2022-12-28 | — | — | EP | disclosed |
| CN-115529392-A | File determination system, file determination method, and information processing apparatus | 精工爱普生株式会社 | 2022-12-27 | — | — | CN | disclosed |
| WO-2022250073-A1 | CONDUCTIVE PASTE AND MULTILAYER SUBSTRATE USING SAME | タツタ電線株式会社 | 2022-12-01 | — | — | WO | disclosed |
| WO-2022074945-A1 | METAL PARTICLE-CONTAINING RESIN COMPOSITION | タツタ電線株式会社 | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078114-A1 | COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF | CDK4, CDK1, CDK3 | ANPEP 3551/4885DPP4 4213/4885NR1H2 843/4885 |
| US-20260143582-A1 | MULTILAYER BODY AND METHOD FOR PRODUCING SAME | LRBA, HSPBP1, FABP4 | ANPEP 3740/4885DPP4 3088/4885NR1H2 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.